BridgeBio Oncology Therapeutics Inc. (BBOT)

NASDAQ

$10.17

+$0.43 (4.41%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$9.60$10.31

Open $9.75

52 Week Range

$8.50$14.87

Previous Close $9.74

Market Cap813.48M

Volume282.20K

Avg Volume286.69K

P/E (TTM)-2.08

EPS (TTM)$-4.89

Dividend / YieldN/A

Dividend StreakN/A

About BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Company Info

SectorHealthcare

IndustryBiotechnology

CEOPedro J. Beltran

Employees62

Websitebbotx.com

Trading Information

Open

$9.75

Previous Close

$9.74

Day High

$10.31

Day Low

$9.60

52 Week High

$14.87

52 Week Low

$8.50